GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells

OBJECTIVE: GW4869 is an exosomal inhibitor. It is necessary to delay the occurrence of gefitinib resistance during non-small-cell lung cancer (NSCLC) treatment. This study aimed to investigate the anti-tumor effects of GW4869 on epithelial-mesenchymal transition (EMT) and expression of extracellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xuan, Fang, Yuting, Du, Jiangzhou, Cai, Shaoxi, Dong, Hangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640835/
https://www.ncbi.nlm.nih.gov/pubmed/38021444
http://dx.doi.org/10.2147/OTT.S428707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640835/
https://www.ncbi.nlm.nih.gov/pubmed/38021444
http://dx.doi.org/10.2147/OTT.S428707

Ejemplares similares